Abnormal Expression of a Novel Apoptosis-Promoting Molecule TFAR19(PDCD5) in the Bone Marrow Cells from Adult Chronic Myeloid Leukemia

阮国瑞,陈珊珊,常艳,付家瑜,王卉,秦亚溱,李金兰,刘艳荣

DOI: https://doi.org/10.3321/j.issn:1671-167x.2002.06.009

2002-01-01

Abstract:Objective: To estimate a novel apoptosis promoting molecule TFAR19 expression in the bone marrow cells from adult chronic myelogenous leukemia (CML) for its significance in the pathogenesis and disease progression of CML. Methods: Flow cytometry (FCM)assay was used for detection of TFAR19 expression in different groups of cells from normal and CML patient bone marrows by 15 monoclonal antibodies with different fluorescent markers. Results: The mean TFAR19 fluorescence intensity was significantly lower in marrow nucleated cells(MNC)from the marrow of 20 untreated CML CP(chronic phase, CP) and 13 CML AP/BP(accelerated or blastic phase, AP/BP)patients than that from the marrow of 10 normal subjects(5 793±1 536 vs 7 260±781, P 0.01; 4 293±1 082 vs 7 260±781, P 0.01, respectively).TFAR19 fluorescence intensity was lower in the marrow granu locytes from CML CP and CML AP/BP patients than that from the normal(6 240±1 734 vs 8 317±726, P 0.01; 5 759±1 487 vs 8 317±725, P 0.01, respectively). Furthermore, the TFAR19 in the marrow lymphocytes from CML CP and CML AP/BP patients it was also lower than that from the normal(1 292±639 vs 2 271±820, P 0.01; 1 231±281 vs 2 271±820, P 0.01, respectively). In addition,in the marrow nucleated cells from CML AP/BP patientsit was further lower than that from CML CP patients (4 293±1 082 vs 5 793±1 536, P 0.01). Conclusion: It can be concluded that TFAR19 expression in marrow nucleated cells was lower in untreated CML patients versus the normal. TFAR19 expression was lower in the marrow granulocytes and lymphocytes with untreated CML CP and CML AP/BP patients versus the normal. It suggests that the abnormality of TFAR19 expression may play an important role in the evolution of CML.